Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
New Scientist on MSN6d
New type of brain cell may tell us when to stop eatingNeurons in the brains of mice tell them to stop eating when they’ve had enough food – and since people probably have the same ...
HealthDay News — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, ...
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
GlobalData on MSN4d
Palatin concludes Phase II trial of combination therapy for obesityPalatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback